ADHD as a Risk Factor for Infection With Covid-19
Background: ADHD limits the ability to comply with Covid-19 prevention recommendations. We hypothesized that ADHD constitutes a risk factor for Covid-19 infection and that pharmacotherapy may lower that risk. Methods: Study population included all subjects (N = 14,022) registered with Leumit Health Services between February 1st and April 30, 2020, who underwent at least one Covid-19 test. Data were collected from the electronic health records. Purchasing consecutively at least three ADHD-medication-prescriptions during past year was considered drug-treatment. Results: A total of 1,416 (10.1%) subjects (aged 2 months-103 years) were Covid-19-positive.They were significantly younger, and had higher rates of ADHD (adjOR 1.58 (95% CI 1.27-1.96, p < .001) than Covid-19-negative subjects. The risk for Covid-19-Positive was higher in untreated-ADHD subjects compared to non-ADHD subjects [crudeOR 1.61 (95% CI 1.36-1.89, p < .001)], while no higher risk was detected in treated ones [crudeOR 1.07 (95% CI 0.78-1.48, p = .65)]. Conclusion: Untreated ADHD seems to constitute a risk factor for Covid-19 infection while drug-treatment ameliorates this effect.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Journal of attention disorders - 25(2021), 13 vom: 15. Nov., Seite 1783-1790 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Merzon, Eugene [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ADHD |
|---|
| Anmerkungen: |
Date Completed 13.09.2021 Date Revised 31.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/1087054720943271 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312732988 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312732988 | ||
| 003 | DE-627 | ||
| 005 | 20231225145040.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/1087054720943271 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1042.xml |
| 035 | |a (DE-627)NLM312732988 | ||
| 035 | |a (NLM)32697120 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Merzon, Eugene |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ADHD as a Risk Factor for Infection With Covid-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.09.2021 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: ADHD limits the ability to comply with Covid-19 prevention recommendations. We hypothesized that ADHD constitutes a risk factor for Covid-19 infection and that pharmacotherapy may lower that risk. Methods: Study population included all subjects (N = 14,022) registered with Leumit Health Services between February 1st and April 30, 2020, who underwent at least one Covid-19 test. Data were collected from the electronic health records. Purchasing consecutively at least three ADHD-medication-prescriptions during past year was considered drug-treatment. Results: A total of 1,416 (10.1%) subjects (aged 2 months-103 years) were Covid-19-positive.They were significantly younger, and had higher rates of ADHD (adjOR 1.58 (95% CI 1.27-1.96, p < .001) than Covid-19-negative subjects. The risk for Covid-19-Positive was higher in untreated-ADHD subjects compared to non-ADHD subjects [crudeOR 1.61 (95% CI 1.36-1.89, p < .001)], while no higher risk was detected in treated ones [crudeOR 1.07 (95% CI 0.78-1.48, p = .65)]. Conclusion: Untreated ADHD seems to constitute a risk factor for Covid-19 infection while drug-treatment ameliorates this effect | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ADHD | |
| 650 | 4 | |a Covid-19 | |
| 650 | 4 | |a prevalence | |
| 650 | 4 | |a stimulants | |
| 650 | 7 | |a Central Nervous System Stimulants |2 NLM | |
| 700 | 1 | |a Manor, Iris |e verfasserin |4 aut | |
| 700 | 1 | |a Rotem, Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Schneider, Tzipporah |e verfasserin |4 aut | |
| 700 | 1 | |a Vinker, Shlomo |e verfasserin |4 aut | |
| 700 | 1 | |a Golan Cohen, Avivit |e verfasserin |4 aut | |
| 700 | 1 | |a Lauden, Ari |e verfasserin |4 aut | |
| 700 | 1 | |a Weizman, Abraham |e verfasserin |4 aut | |
| 700 | 1 | |a Green, Ilan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of attention disorders |d 1997 |g 25(2021), 13 vom: 15. Nov., Seite 1783-1790 |w (DE-627)NLM095560084 |x 1557-1246 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2021 |g number:13 |g day:15 |g month:11 |g pages:1783-1790 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/1087054720943271 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2021 |e 13 |b 15 |c 11 |h 1783-1790 | ||